Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2024-04-12 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞关于2024年度申请综合授信额度并提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding the application for a comprehensive credit line and provision of guarantees for 2024. It details the company's plan to apply for a credit limit of up to RMB 6 billion and provide guarantees for its subsidiaries. The document includes information about the board's approval, the need for shareholder approval, financial data of the subsidiary, and the rationale for the guarantees. It is a formal announcement about financing activities and guarantees, not a financial report or earnings release. The content fits the category of Capital/Financing Update (CAP) as it relates to financing activities and credit facilities.
2024-04-12 Chinese
神州细胞第二届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 10th meeting of the 2nd Board of Directors of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It includes multiple agenda items such as approval of the 2023 annual report, board work report, audit committee reports, financial statements, profit distribution plan, remuneration plans for directors and senior management, and plans for the 2024 fiscal year. The document repeatedly states that the detailed reports and materials are disclosed on the Shanghai Stock Exchange website and that these resolutions will be submitted to the shareholders' meeting for approval. The document is not the actual annual report or financial statements but a formal board meeting resolution announcement summarizing decisions and referring to other detailed reports elsewhere. The document length is 3631 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full report. Therefore, this document fits best into the category of Board/Management Information (MANG), as it announces board meeting decisions and management reports approval rather than containing the full reports themselves.
2024-04-12 Chinese
神州细胞2023年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2023 年年度报告摘要" which translates to "2023 Annual Report Summary". It contains detailed information about the company's business, products, industry analysis, financial data, and management discussion. The length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. It includes financial figures, business overview, risk factors, and management statements, which are typical components of an Annual Report. There is no indication that this is merely an announcement or a certification. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-12 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司2024年度日常关联交易预计事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed opinion from CITIC Securities regarding the 2024 anticipated related-party transactions of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It includes descriptions of the transaction types, amounts, approval procedures by the board, independent directors, and supervisory committee, as well as the rationale and fairness of the transactions. The document is a formal verification or review opinion by the sponsor (CITIC Securities) on the company's related-party transactions for the upcoming year. It does not contain financial statements or quarterly/yearly financial results, nor is it an announcement of voting results or a proxy statement. It is a regulatory compliance-related document focusing on related-party transactions and their fairness, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Annual Report, Interim Report, or Audit Report. The document length is under 5,000 characters, but it is not merely an announcement of a report publication; it is a substantive review opinion document. Therefore, the best classification is Regulatory Filings (RNS).
2024-04-12 Chinese
神州细胞2023年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '2023 年度内部控制审计报告' which translates to '2023 Internal Control Audit Report'. It is issued by PwC (普华永道), a well-known auditing firm, and addresses the effectiveness of internal controls over financial reporting for the fiscal year ending December 31, 2023. The content includes auditor responsibilities, management responsibilities, and an audit opinion on internal control effectiveness. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles. The document is relatively short (872 characters) but contains substantive audit opinion content, not just an announcement or certification. Therefore, it should be classified as AR rather than RNS or RPA. FY 2023
2024-04-12 Chinese
神州细胞2023年度独立董事述职报告（王晓川）
Board/Management Information Classification · 95% confidence The document is titled '2023年度独立董事述职报告' which translates to '2023 Annual Independent Director's Work Report'. It details the independent director's duties, attendance at board and committee meetings, communication with auditors, internal control evaluations, and other governance-related activities during the year 2023. The content focuses on the independent director's report on their responsibilities and observations rather than presenting full financial statements or audit opinions. It is a detailed report on board/management activities and governance oversight rather than a full annual report or audit report. Therefore, the document fits best under the category of Board/Management Information (MANG), as it is a report from a board member about their duties and activities during the year.
2024-04-12 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.